A carregar...
Publicação
Negative MR4·0 chronic myeloid leukaemia and its possible implications for treatment-free remission
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 216.97 KB | Adobe PDF |
Orientador(es)
Resumo(s)
ABL1 tyrosine kinase inhibitors (TKI) have dramatically improved the outcome for chronic myeloid leukaemia (CML) patients, resulting in a life expectancy that approaches that of the general population. Nevertheless, lifelong TKI therapy may have consequences, including chronic adverse events that can substantially impact patients’ quality of life, adherence to therapy and treatment success. Recently, several clinical discontinuation trials have demonstrated that 40–60% of chronic phase CML patients (CP-CML) who have achieved a stable deep molecular response (DMR) can stop therapy without relapsing (Breccia & Foà, 2018). Laboratory recommendations for scoring DMR were previously defined as MR4·0 [either detectable disease ⩽0·01% BCR-ABLIS (MR4·0 positive) or undetectable disease in cDNA with 10 000–31 999 ABL1 transcripts or 24 000–76 999 GUSB transcripts (MR4·0 negative)], MR4·5 [either detectable disease ⩽0·0032% BCR-ABLIS (MR4·5 positive) or undetectable disease in cDNA with 32 000–99 999 ABL1 transcripts or 77 000–239 999 GUSB transcripts (MR4·5 negative)], and MR5·0 [either detectable disease ⩽0·001% BCR-ABLIS (MR5·0 positive) or undetectable disease in cDNA with ⩾100 000 ABL1 transcripts or ⩾240 000 GUSB transcripts (MR5·0 negative)] (Cross et al, 2015).
Descrição
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Palavras-chave
Chronic myeloid leukaemia Treatment-free remission Molecular response level qRT-PCR MR4.0 negative
Contexto Educativo
Citação
Br J Haematol. 2019 Sep;186(6):e181-e184
Editora
John Wiley & Sons, Inc.